April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
The Effects of Pegaptanib Sodium (Macugen®) on Retinal Function in Isolated Perfused Vertebrate Retina
Author Affiliations & Notes
  • J. Beutel
    Department of Ophthalmology, University of Luebeck, Luebeck, Germany
  • K. Januschowski
    Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • K. U. Bartz-Schmidt
    Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • S. Grisanti
    Department of Ophthalmology, University of Luebeck, Luebeck, Germany
  • P. Szurman
    Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • M. Lüke
    Department of Ophthalmology, University of Luebeck, Luebeck, Germany
  • Footnotes
    Commercial Relationships  J. Beutel, None; K. Januschowski, None; K.U. Bartz-Schmidt, None; S. Grisanti, None; P. Szurman, None; M. Lüke, None.
  • Footnotes
    Support  Grant from Eyetech Pharmaceuticals; Pfizer Inc., New York, New York, USA
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 77. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Beutel, K. Januschowski, K. U. Bartz-Schmidt, S. Grisanti, P. Szurman, M. Lüke; The Effects of Pegaptanib Sodium (Macugen®) on Retinal Function in Isolated Perfused Vertebrate Retina. Invest. Ophthalmol. Vis. Sci. 2009;50(13):77.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Nowadays intraocular anti-VEGF therapy is the primary choice in the treatment of neovascular maculopathy. Pegabtanib sodium (Macugen®, Eyetech Pharmaceuticals; Pfizer Inc., New York, New York, USA) inhibits VEGF165 specifically, but is known that all VEGF-A isoforms have also neuroprotective effects avoiding apoptosis of neuronal cells. Therefore, blockage of VEGF165 by pegaptanib sodium could induce retinal dysfunction.

Methods: : Isolated bovine retinas were perfused with an oxygen preincubated nutrient solution. The electroretinogram (ERG) was recorded as a transretinal potential using Ag/AgCl electrodes. Pegaptanib sodium (0.006 mg/mL, 0.06 mg/mL, 0.2 mg/mL according to an intravitreously injected dose of 0.03 mg, 0.3 mg and 1 mg) or the solvent carrier was added to the nutrient solution for 45 min. Thereafter, the retina was reperfused for 75 min with normal nutrient solution. The percentage of a- and b-wave reduction during the application of pegaptanib sodium or the solvent carrier was calculated.

Results: : During the application of the two lower concentrations of pegaptanib sodium (0.006 mg/mL, and 0.06 mg/mL) only a slight not-significant reduction of the b-wave amplitude (p = 0.357 and p = 0.31, respectively) and a-wave amplitude (p = 0.189 and p = 0.46, respectively) was observed. At the highest tested concentration of 0.2 mg/mL a slight not significant improvement of the b-wave amplitude (9.2%, p = 0.11) and a-wave amplitude (8.3%, p = 0.23) was detected. The solvent carrier had no effects on the ERG (p = 0.98 and p = 0.42, respectively). During the washout, the ERG-amplitudes of all test series remained unchanged.

Conclusions: : The present study suggests that pegaptanib sodium with its solvent carrier has a wide safety profile and a good biocompatibility. An intraocular application of 0.3 mg pegaptanib sodium seems to be safe provoking no toxic short-term effects on retinal function.

Keywords: drug toxicity/drug effects • electroretinography: non-clinical • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×